Voraxaze and megludase market seen growing on cancer care demand
The global voraxaze, or megludase, market is forecast to expand through 2035 as cancer cases rise, oncology centers grow and hospitals adopt faster detoxification treatments. North America held the largest regional share in 2025, according to The Business Research Company.
Why it matters: - Voraxaze, also known as megludase or glucarpidase, is used to treat dangerous methotrexate toxicity in cancer patients with delayed drug clearance. - The market matters because it supports emergency oncology care and helps reduce severe chemotherapy complications. - Growth in this market tracks broader demand for supportive cancer treatments, especially in hospitals and oncology centers.
What happened: - The Business Research Company published its Voraxaze and Megludase Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the market is being shaped by advances in cancer treatment and toxicity management. - North America held the largest share of the voraxaze or megludase market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also offered a free sample report and the full market report.
The details: - Voraxaze lowers toxic methotrexate levels in patients who experience delayed clearance due to kidney dysfunction. - The enzyme breaks methotrexate into inactive metabolites that are eliminated through non-renal pathways. - The report links past market growth to better understanding of methotrexate toxicity management, wider use of high-dose chemotherapy, more oncology treatment centers, availability of recombinant enzyme antidotes and greater awareness of kidney-related toxicity risks. - The report expects future growth from precision oncology supportive care, higher investment in emergency oncology therapies, more hospital oncology infrastructure, faster adoption of rapid-response detoxification treatments and continued innovation in enzyme-based antidotes. - Expected trends include greater use of targeted enzyme detoxification therapies, more attention to chemotherapy toxicity management, broader use of emergency oncology support drugs, wider adoption of precision supportive care and stronger hospital-based acute care protocols. - The report cites rising cancer incidence as a core driver of demand. - The American Cancer Society projected 2,001,140 U.S. cancer cases in 2024, up from 1,958,310 in 2023, a 2.19% increase. - The report also points to increased clinical trials as a growth factor. - The National Institutes of Health said about 479,000 clinical trials were registered in the U.S. in 2023, up 9.5% from 437,529 in 2022. - Expansion of oncology care centers is another driver. - The National Institutes of Health said there were 72 National Cancer Institute-designated cancer centers in the U.S. in 2023, up six from the prior year.
Between the lines: - The market is tightly linked to high-intensity cancer treatment, where toxicity management can determine whether chemotherapy continues safely. - Growth in trial activity suggests more clinical attention on antidote therapies and more pathways for adoption in hospital settings. - The report’s regional framing suggests the largest near-term commercial opportunity remains in North America, where oncology infrastructure is already more developed.
What's next: - The Business Research Company expects the market to keep expanding through 2035 as hospital-based oncology care and rapid detoxification protocols become more common. - The report says new editions will add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The company also listed contacts for experts and sales support for readers seeking additional information.
The bottom line: - Voraxaze and megludase remain niche but essential drugs in supportive oncology care, and the market outlook is being driven by higher cancer volumes, more oncology infrastructure and stronger focus on managing chemotherapy toxicity.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
American Business Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.